Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.42 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.42 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23090392 | 0.79 | KMT2A (0.41) | KMT2ANPC1ABCB1ABCC1SLC2A1 | |
| SCHEMBL23105171 | 0.77 | DHODH (0.41) | KMT2AABCB1MEN1NPSR1HSD17B10 | |
| SCHEMBL23090401 | 0.75 | HSD17B10 (0.51) | KMT2ANPC1SLC2A1HTTNPSR1 | |
| SCHEMBL23090369 | 0.74 | SLC2A1 (0.53) | KMT2ASLC2A1HTTMEN1NPSR1 | |
| SCHEMBL17868771 | 0.67 | KMT2A (0.58) | KMT2ANPC1MEN1SMN1; SMN2 | |
| SCHEMBL2238597 | 0.67 | ALDH1A1 (0.60) | KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL14967652 | 0.65 | KMT2A (0.51) | KMT2AHTTMEN1SIGMAR1SMN1; SMN2 | |
| SCHEMBL11389038 | 0.65 | KMT2A (0.67) | KMT2ANPC1ABCB1ABCC1HTT | |
| SCHEMBL13332559 | 0.65 | HSD17B1 (0.51) | KMT2ASLC2A1MEN1HSD17B10 | |
| SCHEMBL2236754 | 0.65 | KMT2A (0.72) | KMT2AHTTMEN1SIGMAR1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11066357-B2 | Benzoannulene derivatives as antiviral agents | SOUTHERN RESEARCH INSTITUTE (US) | 2021-07-20 | — | — | US | disclosed |
| US-11066357-B2 | Benzoannulene derivatives as antiviral agents | SOUTHERN RESEARCH INSTITUTE (US) | 2021-07-20 | — | — | US | disclosed |
| US-20210078937-A1 | BENZOANNULENE DERIVATIVES AS ANTIVIRAL AGENTS | SOUTHERN RESEARCH INSTITUTE | 2021-03-18 | — | — | US | disclosed |
| US-20210078937-A1 | BENZOANNULENE DERIVATIVES AS ANTIVIRAL AGENTS | SOUTHERN RESEARCH INSTITUTE | 2021-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210078937-A1 | BENZOANNULENE DERIVATIVES AS ANTIVIRAL AGENTS | ZC3HAV1, MAVS, ZC3HAV1L | KMT2A 3836/4885NPC1 1391/4885ABCB1 1462/4885 |
| US-11066357-B2 | Benzoannulene derivatives as antiviral agents | ZC3HAV1, MAVS, ZC3HAV1L | KMT2A 3836/4885NPC1 1391/4885ABCB1 1462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.